(Q35205528)

7 August 2017

1 reference

title

Treatment options for relapsed acute promyelocytic leukaemia (English)

1 reference

7 August 2017

1 reference

Elihu H Estey

1

1 reference

7 August 2017

publication date

1 September 2003

1 reference

Best Practice and Research: Clinical Haematology

7 August 2017

published in

1 reference

7 August 2017

volume

16

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

521-534

1 reference

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Acute promyelocytic leukemia: evolving therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676)

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900039-2

7 January 2021

10.1016/S1521-6926(03)00039-2

Identifiers

DOI

1 reference

release_x6m2usdfenhttoizzrhxvlldim

7 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x6m2usdfenhttoizzrhxvlldim

24 November 2022

mapped directly with Wikidata item

1 reference